AMSTERDAM, The Netherlands. 20th January 2020, 12:00 BST / CET. Norgine B.V. (Norgine) today announced that Dr Michael Lange has been appointed as General Manager Germany with effect from 15th January 2020
Michael Lange joins Norgine from Celgene and Amgen respectively, where he worked for a short time after the sale of the psoriasis Business Unit. At Celgene he most recently worked as Business Unit Director Immunology and Inflammation in Germany.
He was leading a business turnaround for a psoriasis product and in launch preparation for a multiple sclerosis (MS) product, before Celgene's acquisition by Bristol-Myers Squibb.
During his career, Michael has held a number of increasingly senior roles in sales, marketing, medical affairs and market access with several pharmaceutical companies including Aventis Pharma, AstraZeneca and GlaxoSmithKline.
He has spent most of his working life in Germany but also many years in the United States and the UK.
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2019 and generated >€425 million in net product sales, a growth of 7% over 2018.
Norgine has a direct presence in 14 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.
In 2012, Norgine established Norgine Ventures, a complementary business which supports innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.